Kilmer Lucas is a leading healthcare-only investor relations firm.
Employing an "outsourced in-house" partnership model, we design and execute customized IR programs for medical device, drug development, cell therapy, diagnostics and healthcare services companies.
While many competing firms are comprised of former bankers and sell-side analysts, Kilmer Lucas is led by senior practitioners with decades of internal IR function experience. To us, that is a fundamental point of differentiation. It gives Kilmer Lucas a unique "inside-looking-out" orientation that drives a proactive communications approach usually only associated with the most well-developed in-house IR departments.